Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Post by SABBOBCATon Feb 13, 2023 5:43pm
463 Views
Post# 35284005

Odds

Odds

Well we know that in the next two weeks we will hear from mananagement about 2022 earnings, and the CMO speaks on the 21st at a conference. So while it is frustrating that the company has been relatively silent for almost a quarter, news should start flowing in the very near term. Does anyone want to take a crack at the odds that the SP will recover to pre-pause levels in the coming weeks? 

If you would have asked me a month ago I would have felt fairly confident we would recover, but the longer this drags out the more I am questioning the future. Judging by the other comments on this board, I am not alone.


Perhaps TH will use Valentine's Day to woo current and prospective investors with some positive news?  I want to love them, but having received no card, let alone chocolate, flowers, or dinner, since 2018, maybe this is the year they get kicked to the curb lol 

<< Previous
Bullboard Posts
Next >>